584
Participants
Start Date
December 13, 2013
Primary Completion Date
December 12, 2016
Study Completion Date
March 1, 2017
Placebo
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
MEDI9929 70 mg
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
MEDI9929 210 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
MEDI9929 280 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Research Site, Riga
Research Site, Budapest
Research Site, Middelburg
Research Site, Budapest
Research Site, Sofia
Research Site, Sofia
Research Site, Sofia
Research Site, Budapest
Research Site, Sofia
Research Site, Sofia
Research Site, Törökbálint
Research Site, Gödöllő
Research Site, Százhalombatta
Research Site, Balassagyarmat
Research Site, Komárom
Research Site, Plovdiv
Research Site, Debrecen
Research Site, Durban
Research Site, Velingrad
Research Site, Mátészalka
Research Site, Farkasgyepü
Research Site, Nagykanizsa
Research Site, Csorna
Research Site, New York
Research Site, New York
Research Site, Belgrade
Research Site, Prague
Research Site, Vinnytsia
Research Site, Kamenitz
Research Site, Baltimore
Research Site, Richmond
Research Site, Charlotte
Research Site, Charlotte
Research Site, Spartanburg
Research Site, Rock Hill
Research Site, Savannah
Research Site, Oviedo
Research Site, Miami
Research Site, Kragujevac
Research Site, Haifa
Research Site, Suprunivka Vil., Poltava Regio
Research Site, Poltava
Research Site, Strakonice
Research Site, Dublin
Research Site, Kfar Saba
Research Site, Dnipropetrovsk
Research Site, Tel Litwinsky
Research Site, Mykolayiv
Research Site, Rochester
Research Site, Peoria
Research Site, Odesa
Research Site, Zaporizhzhya
Research Site, Zaporizhzhya
Research Site, Oklahoma City
Research Site, Ivano-Frankivsk
Research Site, Houston
Research Site, Ashkelon
Research Site, Bratislava
Research Site, Los Angeles
Research Site, Los Angeles
Research Site, Jerusalem
Research Site, Klaipėda
Research Site, Klaipėda
Research Site, Šurany
Research Site, Štúrovo
Research Site, Topoľčany
Research Site, Zvolen
Research Site, Rehovot
Research Site, Brandýs nad Labem
Research Site, Hradec Králové
Research Site, Mladá Boleslav
Research Site, Prague
Research Site, Prague
Research Site, Szeged
Research Site, Petah Tikva
Research Site, Chūōku
Research Site, Chūōku
Research Site, Chūōku
Research Site, Fujisawa-shi
Research Site, Kiyose-shi
Research Site, Kurume-shi
Research Site, Maebashi
Research Site, Ora-gun
Research Site, Sagamihara-shi
Research Site, Saitama-Ken
Research Site, Sapporo
Research Site, Taito-ku
Research Site, Toshima-ku
Research Site, Yokkaichi-shi
Research Site, Daugavpils
Research Site, Rēzekne
Research Site, Riga
Research Site, Riga
Research Site, Riga
Research Site, Kaunas
Research Site, Bardejov
Research Site, Ilava
Research Site, Košice
Research Site, Levice
Research Site, Nové Zámky
Research Site, Poprad
Research Site, Spišská Nová Ves
Research Site, Pretoria
Research Site, Pretoria
Research Site, Kyiv
Research Site, Kyiv
Research Site, Kyiv
Lead Sponsor
Collaborators (1)
Amgen
INDUSTRY
MedImmune LLC
INDUSTRY